Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Jacek HajdaBarbara LeuchsAssia L AngelovaVeronika FrehtmanJean RommelaereMieke MertensMaximilian PilzMeinhard KieserOttheinz KrebsMichael DahmBernard HuberChristine E EngelandAthanasios MavratzasNicolas HohmannJutta SchreiberDirk JägerNiels HalamaOliver SedlaczekMatthias M GaidaVolker DanielChristoph SpringfeldGuy Ungerechts

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The trial met all primary objectives, revealed no environmental risks, and indicated favorable immune modulation after administration of ParvOryx. It can be considered a good basis for further systematic clinical development alone or in combination with immunomodulatory compounds.

Keyphrases

human health
study protocol
phase iii
clinical trial
risk assessment
phase ii
single cell
tyrosine kinase
randomized controlled trial
stem cells
cell therapy
open label